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Background: Within the past two decades, Candida species have emerged as major human pathogens and are currently the 
fourth most common cause of nosocomial infection. Propose of this study was to determine the occurrence of oral 
Candidiasis among cancer patients at Qods hospitals in Sanandaj.  
Materials and Methods: Sixty cancer patients were examined for oral candidiasis. For all patients, the clinical diagnosis had 
to be confirmed microbiologically by the presence of yeasts and / or hyphae or pseudohyphae on potassium hydroxide–
treated smears of oral swabs. Oral samples were obtained and cultured on Sabouraud's dextrose agar and CHROMagar. 
Results: 25 out of the 60 patients (41.7%) were males and 35 (58.3%) were females ranging in age from 15 to 79 years. Gastro-
intestinal cancer and Breast cancer were the most frequent cancer in the studied group, accounting for 65 % and 18.4 % 
respectively.  The mean weight of the patients was 52.67 Kg  (range, 38– 80 Kg). Similarly, the mean of hospital stay was 3.58 
days (range; 1-9 days). 
From these patients, 19 Candida spp were isolated; C. albicans alone outnumbered other species and accounted for 73.68% 
episodes of trash.  
For C. albicans isolates, the MIC values ranges from 1 to 9 µ g / ml µg / ml for polyenes and from 0.03 to 16  µ g / ml for the 
azole antifungals. All the Candida albicans had closely related MFCs values. 
Conclusion: In conclusions, the finding of our study strongly suggest that oral candidiasis is a frequent complication among 
cancer patients, being C. albicans the main etiological agent. 
Keywords: Cancer, Oral candidiasis, Candida albicans, Antifungal agents 
 
INTRODUCTION 
The ubiquitous candida spp are important cause of 
oropharyngeal candidiasis and nosocomial 
infections including life threatening infections 
among cancer patients. Indeed oropharyngeal 
candidiasis is a common infection in cancer patients 
and ranks as the most common fungal diseases [1]. 
Among candida spp, the most frequently 
encountered clinical problem is caused by C. albicans 
[2]. Actually many people are colonized by Candida 
spp as a commensal organism. For this reason, 
cancer patients must be strictly monitored for the 
clinical presence of yeast.    
 
 
The use of broad – spectrum antibiotics, steroids, or 
other immunosuppressive agents, diabetes mellitus, 
cancer patients and organ transplantation can 
increase the risk for candidal infections [3]. The 
prevalence of oral candidiasis in various countries 
varies among studies according to location, age of 




reported to range from 20- 75% [4].  The incidence of 
Candida spp isolated from the oral cavity has been 
reported to be 45 % - 65% in children, 50-65% in 
people with removable dentures, 65-88% in those 
residing in acute and long term care facilities, 90% 
in patients with acute leukemia, 95% with HIV [4-6]. 
Among cancer patients, infection can spread 
through the bloodstream, leading to sever infection 
with significant morbidity and mortality [7]. A 
routine oral examination of cancer patients has 
revealed a greater incidence of Candida infections 
than that in most types of patients. Almost all 
surveys on fungal infections in cancer patients come 
from USA, Europe, and other developed countries, 
and little is known about this problem in 
developing countries particularly Iran. For the first 
time we report on occurrence rate of oral Candidiasis 
among cancer patients at  Qods hospitals in 
Sanandaj and in-vitro susceptibility to antifungal 









MATERIALS AND METHODS 
This study was conducted over a period of 16 
months at Qods hospital of the Kurdistan 
University of Medical Sciences. Patients who had 
developed oral thrush and were treated at the 
department of medical oncology were eligible for 
the study.  
All the patients had different types of cancers and 
after taking the sample, had received different types  
of chemotherapy / radiotherapy prescribed by 
attending physicians.  Oral candidiasis was 
clinically diagnosed by investigator. The clinical 
diagnosis was based on lesions clinically recognized 
as creamy, whitish, curd-like plaques or 
pseudomembranes involving the oropharyngeal 
mucosa and the tongue. For all patients, the clinical 
diagnosis had to be confirmed microbiologically by 
the presence of yeasts and / or hyphae or 
pseudohyphae on potassium hydroxide–treated 
smears of oral swabs. Swab was also used for yeast 
cultures on plates with Sabouraud dextrose agar. 
Cultures were considered positive if ≥10 CFU 
appeared on the plate. Candida spp were identified 
by classical methods [8]. The differential medium 
Chromagar Candida was used to confirm the results 
by colony morphology and pigmentation according 
to the manufacture's instructions. 
Minimum Inhibition Concentration (MIC) was 
determined by serial broth dilution method [9]. 
Briefly, a serial dilution was made from the stock 
solution of the antifungal agents to have the final 
concentration ranges from 0,03 to 16 µg / ml for 
amphotericin B, Ketoconazole and miconazole; 
0.125 to 64 µg / ml for fluconazole, and 0.7 to 18.5 
µg / ml for nystatin.  
The prepared inocula of Candida spp were incubated 
with different antifungal concentration at 300C.  
Aliquot from each isolate showing inhibition was 
inoculated on the surface of SDA plate and 
incubated at 300C for 24 – 48 hours to determine the 
MFC of the respective antifungal agent.  
 
RESULTS 
During a 16 months period (March 2009 to 
September  2010), 60 patients from Qods hospital in 
Sanandaj were analyzed for oral Candidiasis among 
cancer patients. Twenty five out of the 60 patients 
(41.7%) were males and 35 (58.3%) were females 
ranging in age from 15 years to 79 years.  
Gastro-intestinal cancer and Breast cancer were the 
most frequent cancer in the studied group, 
accounting for 65 % and 18.4 % respectively.  The 
mean weight of the patients was 52.67 Kg  (range, 
38– 80 Kg). Similarly, the mean of hospital stay was 
3.58 days (range; 1-9 days). 
From these patients, 19 Candida spp were isolated; 
C. albicans alone outnumbered other species and 
accounted for 73.68% episodes of trash.  
For C. albicans isolates, the MIC values ranges from 
9 to 18 µ g / ml for polyenes and from 16 to 64  µ g / 
ml for the azole antifungals. All the Candida albicans 
had closely related MFCs values. 
 
TABLE 1: DEMOGRAPHIC CHARACTERISTICS  
OF CANCER PATIENTS WITH CANDIDIASIS  
Patient characteristic 
Sex No. (%) 
Male 25 ( 41.7) 
Female 35 (58.3) 
Age (years) 
Range 15 – 79 
Mean 49.88 
Weight (Kg) 
Range  38-80 
Mean  52.67 




GI 39 (65) 
Lung 6 (10) 
Breast 11 (18.4) 
Head and Neck 2 (3.3) 




TABLE 2: FREQUENCY OF ISOLATION 
OF CANDIDA SPECIES FROM 60 CANCER 
PATIENTS WITH ORAL CANDIDIASIS 
Candida spp Number (%) 
Candida albicans 14 (73.68) 
Candida krusi 05 (26.32) 




Candidal infections are a major problem in the 
world, especially among the cancer patients [10-11]. 
The epidemiology of C. albicans and other yeasts 
from the oral cavity of patients  
with cancer is quite varied.  
Our patient population consisted of 60 individuals 





intestinal cancer and Breast cancer were the most 
frequent cancer in the studied group, accounting for 
65 % and 18.4 % respectively which is in accordance 
to other investigation [12]. 
 
TABLE 3: MIC AND MFC PROFILE OF CANDIDA SPP.  
ISOLATED FROM CANCER 
PATIENTS WITH ORAL CANDIDIASIS 
 
Antifungal agents MIC 
MFC 
C. albicans 
Amphotericin B MIC 
MFC 
16  µ g / ml 
≤ 16 µ g / ml 
Nystatin MIC 
MFC 
≥9 -18 µ g / ml 
≤ 18 µ g / ml 
Fluconazole MIC 
MFC 
≥ 32 -64 µ g / ml 
≤ 64  µ g / ml 
Ketokonazole MIC 
MFC 
16  µ g / ml 
≤ 16 µ g / ml 
 
Results obtained in this study established several 
points pertinent to the prevalence of oral 
candidiasis consistent with published data [13-14]. 
Nineteen Candida spp were isolated from the oral 
cavity of 60 cancer patients. As shown in Table 2, C. 
albicans alone outnumbered other species  and 
accounted for 73.68% episodes of oral candidiasis. 
Our findings were consistent with that noted by 
other investigators [15-16]. 
Bagg et al. [17] showed that patients with advanced 
cancer have demonstrated a high incidence (51%) of 
oral colonization with non-C. albicans yeasts [18].  
Antifungal drug resistance of Candida spp 
continues to increase in response to the widespread 
of application of antifungal agents in treatment of 
cancer patients. MIC and MFC  data for the two 
polyenes (amphotericinn B and nystatin ) and for 
the two azoles ( flucobazole, and Ketoconazole ) are 
in general agreement with others studies conducted 
in close geographical regions [19-20].  
In conclusions, the finding of our study strongly 
suggest that oral candidiasis is a frequent 
complication among cancer patients, being C. 
albicans the main etiological agent; Most isolates of 
Candida spp. tested were very resistant to Polene as 
well as azole groups. The frequent occurrence of 
Candida albicans in oral cavity of cancer patients 
indicates a need for effective management of the 
infection prior to any anticancer treatment, as severe 
complications can otherwise result. 
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